6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $809000 | -$22M | 1129.4% | -2233.5% | -$18M | — | $27M |
| 2024 | $0 | -$6M | — | — | -$6M | — | $27M |
| 2023 | $0 | $8M | — | — | -$3M | — | $26M |
| 2022 | $34M | $8M | 59.7% | 31.5% | $9M | — | $23M |
| 2021 | $34M | $8M | 59.7% | 32.9% | $7M | — | $17M |
| 2020 | $31M | $6M | 61.4% | 28.7% | — | — | — |
How the market has priced LICN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Lichen International Ltd's revenue has declined 51.7% per year. These are computed facts, not advice.
As of FY2025, Lichen International Ltd reported — of total debt against $27M of cash.
In FY2025, gross margin was 1129.4%, operating margin -2233.5%, and net margin -2714.7%.
As of Jun '26, Lichen International Ltd traded at a price-to-earnings ratio of about 1.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.